Tag: EMA

ISPOR’s 1st PLENARY OF 18th ANNUAL EUROPEAN CONGRESS FOCUSES ON LIFECYCLE APPROACH TO DECISION MAKING ON HEALTH TECHNOLOGIES

Milan, Italy—November 9, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress first plenary session — Strategy in Motion: The Current and Future

Posted in Announcements, ISPOR News & Press Tagged with: , , , , , , ,

WHAT`S GOING ON WITH THE TURKISH ORPHAN DRUGS MARKET?

Ankara, Turkey – Many countries and regions have already defined health policies on orphan drugs for rare diseases. Although there is no official definition in Turkey, all orphan drugs are covered by reimbursement, regardless of their market authorization status.

Posted in Announcements, Health Policy Analyses, Value in Health Regional Issues Tagged with: , , , , , , , ,

Collaboration Between Regulators And HTA Organizations To Improve Health Care Decision Making

PRINCETON, NJ, June 25, 2014 (ISPOR) — As announced today by the European network for Health Technology Assessment (EUnetHTA) and European Medicines Agency (EMA), Value in Health, the official journal for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), was pleased to publish

Posted in ISPOR News & Press, Value in Health Tagged with: , , ,